MedPath

A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantatio

Phase 1
Conditions
Standard primary treatment-refractory acute GVHD
Registration Number
JPRN-UMIN000001716
Lead Sponsor
JCR pharmaceuticals Co.,Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

*Patients who had the acute GVHD therapy except standard therapy with corticosteroids. *Patients who had the hematopoietic transplantation while their malignant disease was not remitted (except for the patients who have little possibility of early relapse). *Oxygen gas saturation in rest < 94%.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effectiveness of GVHD treatment from the first dose point to 4 weeks later and others
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath